JSES International 6 (2022) 241-246

Contents lists available at ScienceDirect

JSES International

journal homepage: www.jsesinternational.org

Parkinson's disease and shoulder arthroplasty: a systematic review



Erick M. Marigi, MD^a, Harsh Shah, MPH, MS^b, John W. Sperling Jr. ^{a,*}, Leslie C. Hassett, MLS^c, Bradley S. Schoch, MD^d, Joaquin Sanchez-Sotelo, MD, PhD^a, John W. Sperling, MD, MBA^a

^aDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA ^bMayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, USA ^cMayo Clinic Libraries, Mayo Clinic, Rochester, MN, USA ^dDepartment of Orthopedic Surgery, Mayo Clinic, Jacksonville, FL, USA

ARTICLE INFO

Keywords: Shoulder arthroplasty Parkinson's disease Hemiarthroplasty Anatomic total shoulder arthroplasty Revision shoulder arthroplasty Reverse total shoulder arthroplasty

Level of Evidence: Level IV; Systematic Review

Background: Parkinson's disease (PD) is a neurodegenerative disorder associated with inferior clinical outcomes after surgical management of many orthopedic conditions. The purpose of this systematic review was to define the clinical, functional, and patient-reported outcomes of shoulder arthroplasty (SA) in patients with PD.

Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search was completed using the Ovid platform for searches in MEDLINE, EMBASE, Cochrane Central, and Cochrane Systematic Reviews, with additional searches in Web of Science and Scopus. Included studies were full-length, English-language, clinical investigations reporting on SA in patients with PD with at least one clinical outcome.

Results: Seven studies including 7126 patients (7134 SA) met inclusion criteria with a mean age of 72.6 (range, 69.5–75.8 years), 58.9% female, and the average follow-up duration was 65 months (range, 17–119 months). Anatomic total shoulder arthroplasty (aTSA) was the most reported implant surgery (n = 3455, 48.4%) followed by hemiarthroplasty (HA) (n = 2840, 39.8%), and reverse shoulder arthroplasty (RSA) (n = 839,1.8%). SA consistently improved pain. Forward elevation, abduction, and external rotation had a pooled mean increase of 36°, 20°, and 6°, respectively. Complications occurred at a pooled rate of 22.5%, with stiffness (7.1%), need for revision (5.3%), and instability (4.7%) as the most common complications reported. Reoperations inclusive of revisions occurred at a lower pooled rate of 5.6%, with aTSA (n = 201; 9.0%) having the highest rate, followed by HA (n = 158; 7.1%), and then RSA (n = 42; 1.9%). **Conclusions:** The results of the present systematic review demonstrate that SA in patients with PD results in consistent patients without PD, likely due to the neurodegenerative manifestations of this disorder. In addition, RSA had a lower reoperation rate than HA and aTSA in patients with PD.

© 2021 The Authors. Published by Elsevier Inc. on behalf of American Shoulder and Elbow Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease.⁸ The annual incidence of PD is 20.5 cases per 100,000 individuals, with a lifetime risk of 2% in men and 1.3% in women.^{8,11} Disease onset typically follows a progressive course after 50 years of age with a wide spectrum of clinical symptoms.¹³ Motor symptoms include bradykinesia, muscle rigidity, flexed posture, asymmetric limb resting tremor, and postural instability, while nonmotor symptoms are cognitive impairment and depression.^{13,16} In orthopedics, prior investigations have demonstrated successful pain relief but marginal functional benefits and increased perioperative complications after total knee and hip arthroplasties in patients with PD.^{12,14,17} The limited functional results after lower limb arthroplasty were attributed to certain clinical disease symptoms, such as severe tremor, preexisting muscle rigidity, and dystonia.^{1,12,14,17} Although most of the arthroplasty studies in patients with PD has been conducted on the lower extremity, the upper extremity is more commonly involved with tremor and choreiform movement.⁶ As such, some have proposed even greater rates of failure and complication rates in patients with PD after shoulder arthroplasty (SA).^{7,9,10}

The current literature evaluating SA in patients with PD is generally limited to small retrospective studies and case reports. 9,10

https://doi.org/10.1016/j.jseint.2021.11.004

Mayo Clinic Institutional Review Board approved this study (PR12-007498-04). *Corresponding author: John W. Sperling, MD, MBA, Mayo Clinic, 200 First Street

SW, Rochester MN 55905, USA.

E-mail address: Sperling.John@mayo.edu (J.W. Sperling).

^{2666-6383/© 2021} The Authors. Published by Elsevier Inc. on behalf of American Shoulder and Elbow Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).



Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) flowchart of articles identified.

Publications available to date do suggest that patients with PD are at higher risk for complications after any type of SA because of the various motor, cognitive, and metabolic factors arising from the neurodegenerative pathology.⁵ However, characterizing and comparing the perioperative complications in patients with PD undergoing SA has been difficult because of the relatively low incidence of these procedures in patients with the disease. As such, the purpose of this study was to systematically review the evidence in the current literature to evaluate the clinical, functional, and patient-reported outcomes of SA in patients with PD.

Methods

Literature search

This systematic review investigating the outcomes of PD in SA was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta analyses) 27-item checklist (Fig. 1). The comprehensive literature review was completed on June 8, 2021, using MEDLINE, Embase, and Cochrane, Web of Science, and Scopus library databases. Search terms included "Parkinson's disease", "Parkinson's", "shoulder arthroplasty", "shoulder replacement", "hemiarthroplasty", "anatomic total shoulder arthroplasty". The formal

strategy listing all search terms used and how they are combined is included in the Supplementary Appendix S1.

Eligibility criteria and study selection

The inclusion criteria consisted of full-length publications written in the English language, publication in a peer-reviewed journal, level IV evidence or higher, and presence of at least 1 reported clinical outcome (common shoulder functional outcomes, complications, reoperations, or readmission). Exclusions entailed abstract-only reports, case reports, expert opinions, literature reviews, and studies with no reported outcomes.

Data extraction

The search strategy was designed and conducted by an experienced librarian with input from the study investigators. Study demographics were subsequently collected by 2 blinded reviewers. These included the articles' author, publication year, study design, and level of evidence. Further patient-specific characteristics collected included sample size, mean age, sex, follow-up interval, arthroplasty type, functional outcome data, radiographic outcome data, complication rates, reoperations, and patient-reported outcome measures. Study characteristics and patient demographics.

Study	LOE	No. of patients	All SA	HA	Implants TSA	RSA	Age, yr	Male sex, n (%)	Follow-up, mo
Koch et al (1997) ⁷	IV	15	16	_	16	_	70	7 (43.8)	64
Kryzac et al (2009) ⁹	IV	42	49	-	49	_	70	32 (65.3)	96
Kryzac et al (2010) ¹⁰	IV	7	7	7	_	_	72	5 (71.4)	119
Dunn et al (2011) ⁵	IV	3	3	-	_	3	75	0 (0)	17
Burrus et al (2015) ³	III	7032	7032	2833	3390	809		2874 (40.9)	NR
Cusick et al (2017) ⁴	III	10	10	-	-	10	76	4 (40)	43
Borbas et al (2021) ²	III	17	17	-	_	17	74	7 (41.2)	50
Total	_	7126	7134	2840 (39.8%)	3455 (48.4%)	839 (11.8%)	72.7	2929/7134 (41.1)	65

LOE, level of evidence; *SA*, shoulder arthroplasty; *HA*, hemiarthroplasty; *TSA*, total shoulder arthroplasty; *RSA*, reverse shoulder arthroplasty; *NR*, not reported. All values are reported as the number and percentage except when noted.

Statistical analysis

Statistical analysis was performed with the combination of Microsoft Excel (Version 16.0.1; Microsoft Corp., Redmond, WA, USA) and JMP Pro (Version 14.1.0; SAS Institute, Cary, NC, USA). Descriptive statistics were presented as means, medians, percentages, and standard deviation when appropriate. Continuous variables were analyzed using Student t tests or Wilcoxon rank-sum tests. Categorical variables were analyzed using Chi-square analysis or Fisher exact tests. When available, raw data were extracted and reported as pooled means if possible. Investigations with individual raw patient data without means and standard deviations were manually included into Microsoft Excel for inclusion into the final calculations. *P* values < .05 were considered statistically significant.

Results

Study characteristics and patient demographics

The initial literature search resulted in 29 total studies. No duplicates were present, and all 29 studies were screened for inclusion and exclusion criteria. Subsequently, 17 unique studies were identified as potentially relevant, and full texts were assessed for eligibility. Seven clinical studies met criteria to be included in this systematic review, as demonstrated in Figure 1. A total of 7134 shoulders in 7126 patients were included in the analysis. Mean patient age at the time of arthroplasty was 72.6 (range, 69.5 – 75.8) years, 58.9% were female, and the average follow-up duration was 65 months (range, 17 – 119 months). Anatomic total shoulder arthroplasty (aTSA) was the most reported implant procedure (n = 3455, 48.4%), followed by hemiarthroplasty (RSA) (n = 839, 11.8%) (Table I).

Clinical and functional outcome measures

Six out of the seven studies (n = 102) reported pain as an outcome measure, all reporting general improvement after SA (Table II).^{2,4,5,7,9,10} Three studies (n = 30) measured forward elevation, with a pooled postoperative mean of 75°.^{2,4,5} Of these investigations, two had preoperative data available demonstrating a pooled mean increase of 36° postoperatively.^{2,4} Five studies (n = 99) measured abduction, with a pooled postoperative mean 97° and a mean increase of 20° postoperatively.^{2,4,7,9,10} Six studies (n = 102) measured external rotation, with a pooled postoperative mean of 27° and a mean increase of 6° postoperatively.^{2,4,5,7,9,10} Five studies (n = 99) measured internal rotation with various reporting scales, none demonstrated any significant improvements from baseline (Table II).^{2,4,7,9,10}

Cusick et al⁴ (n = 10) was the only study to report American Shoulder and Elbow Surgeons score (ASES) and simple shoulder test outcomes with a mean improvement of 33.7 to 51.0 (P = .047) and 1.3 to 3.8 (P = .024), respectively. Borbas et al² (n = 17) was the only study to report SSV, absolute Constant-Murley score, and relative Constant-Murley bow score with mean improvements of 33.9 to 57.8 (P = .005), 26.8 to 48.7 (P < .001), and 35 to 61.5 (P < .001), respectively. Three studies (n = 66) reported outcome measures using the Neer result rating scale, with pooled categories of 24% excellent, 26% satisfactory, and 50% unsatisfactory.^{7,9,10}

Shoulder-related complications, reoperations, and revisions

All studies reported on postoperative complications with a pooled rate of 22.5% (1607/7134) (Table III). Stiffness was the most common pooled complication (n = 505; 7.1%), followed by an unlisted need for revision (n = 381; 5.3%), and then instability (n = 381; 4.7%). When tiered by implant, stiffness, need for revision, and instability remained the top three categories for HA, TSA, and RSA (Table IV). Reoperations inclusive of revisions occurred at a pooled rate of 5.6% (401/7134), with revisions accounting for 398 of 401 reoperations also occurring at a pooled rate of 5.6%. When categorized by implants, aTSA had the highest reoperation rate (n = 201; 9.0%) followed by HA (n = 158; 7.1%), and then RSA (n = 42; 1.9%).

Discussion

PD is a neurodegenerative disorder that presents a clinical challenge with respect to surgical management of orthopedic conditions, including SA. Studies examining outcomes of SA in PD are scarce, with the available data limited to smaller retrospective investigations. The results of our systematic review indicate that SA provided patients with PD adequate pain relief. However, functional benefits after SA remained limited, with small increases in ROM and marginal patient-reported outcome improvements. Complications occurred at a pooled rate of 22.5%, with stiffness (7.1%), need for revision (5.3%), and instability (4.7%) as the most common issues. Despite this, reoperations inclusive of revisions occurred at a lower pooled rate of 5.6%, with aTSA (9.0%) having the highest rate, followed by HA (7.1%), and RSA (1.9%) with the lowest rate.

The clinical studies included in this review all demonstrated improvement in pain after SA. Koch et al⁷ first evaluated the effects of SA in 15 PD patients, demonstrating discouraging functional results but reasonable success in pain relief after unconstrained aTSA. In a further review of subsequent studies with matched cohorts, Cusick et al⁴ demonstrated similar postoperative VAS pain and ASES pain scores of PD patients to a matched RSA cohort. Similarly, Borbas et al² observed equivalent pain improvement after RSA in patients with PD compared with their matched cohort. Unlike pain relief, functional improvement in this cohort has historically been poor.⁷ In the present review, forward elevation had a pooled postoperative mean of 75° with mean increases of

					Nalige of Illoud.	(caaigan) n		ביווו ובלחוובר					Neer result rating
De	scriptive	VAS	NRS	FE	ABD	ER	IR	ASES	SSV	SST	aCS	rCS	
Koch et al $(1997)^7$ Pr	e: 38% severe	Pre: NR	Pre: NR	Pre: NR	Pre: 106 ± 33	Pre: 29 ± 24	Pre: L4	Pre: NR	Pre: NR	Pre: NR	Pre: NR	Pre: NR	25% Excellent 13% Satisfactory
Po	st: 6% severe	Post: NR	Post: NR	Post: NR	Post: 98 ± 36	Post: 45 ± 27	Post: L4	Post: NR	Post: NR	Post: NR	Post: NR	Post: NR	62% Unsatisfactory
Kryzac et al (2009) ⁹ NF	~	4.6	NR	NR	100	21	Sacrum	NR	NR	NR	NR	NR	23% Excellent
													30% Satisfactory
NF	~	1.8	NR	NR	119	44	L5	NR	NR	NR	NR	NR	
Kryzac et al (2010) ¹⁰ NF	~	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	29% Excellent
													29% Satisfactory
													43% Unsatisfactory
2.5	5/5	NR	NR	NR	97	38	Sacrum	NR	NR	NR	NR	NR	
Dunn et al (2011) ⁵ NF	~	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
NF	~	0.7	NR	41 ± 20	NR	8.3 ± 7.6	NR	NR	NR	NR	NR	NR	
Burrus et al (2015) ³ NF	~	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
NF	~	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Cusick et al (2017) ⁴ NF	~	6.3 ± 1.2	NR	48 ± 34	48 ± 27	23 ± 21	1.3 ± 0.9	33.7 ± 18.6	NR	1.3 ± 1.1	NR	NR	
NF	~	3.9 ± 1.2	NR	91 ± 34	80 ± 27	16 ± 21	2.3 ± 0.9	51.0 ± 18.6	NR	3.8 ± 1.1	NR	NR	
Borbas et al (2021) ² NF	~	NR	6.8 ± 4.7	64 ± 34	56 ± 23	20 ± 17	3.2 ± 2.1	NR	33.9 ± 17.7	NR	26.8 ± 14.6	35 ± 17.7	
NF	~	NR	12.4 ± 3.3	92 ± 32	92 ± 31	10 ± 16	3.4 ± 1.5	NR	57.8 ± 27.8	NR	48.7 ± 14.6	61.5 ± 18.3	

abduction to 36° and external rotation to 6°, with these differences remaining below the described minimal clinically important differences after TSA and RSA.¹⁵

In addition, patient-reported outcomes and satisfaction were also marginal. In studies including the Neer rating scale, up to 50% of SA had an unsatisfactory result, notably implants included were either HA or aTSA.^{7,9,10} Despite this, some benefits after RSA have been reported by Cusick et al,⁴ with improvements of ASES and simple shoulder test similar to matched controls. Borbas et al² also noticed improvement in SSV, absolute Constant-Murley score, and relative Constant-Murley bow score but at lower postoperative values than matched RSA controls. These outcomes are likely affected by the poor muscle control, rigidity, and bradykinesia of PD, which may limit the ability of SA and associated implants to improve the compromised shoulder girdle. To combat this, modifications of the surgical technique to include appropriate soft-tissue releases, optimized component positioning, early mobilization, prolonged physical therapy, and botulinum toxin A use have been described with unclear benefits.^{2-5,7,9,10}

In this review, complications remained a notable problem, with a pooled rate of 22.5%. Postoperative stiffness was the most often described complication, at a rate of 7.1%, which is consistent with the ROM findings in the literature. Although soft-tissue tension and component positioning play a role in subsequent ROM, the ability to successfully engage in physical therapy likely also contributes to the outcome. As such, the combination of rigidity, bradykinesia, and dementia may translate into a limited ceiling for postoperative ROM improvements in these patients. Instability was also observed at an elevated rate of 4.7%. Initial investigations highlighted that this may be an issue limited to unconstrained SA, but more recent studies including this review continued to demonstrate higher rates of instability in RSA as well.^{2,4} As patients with PD have asynchronous motor function, constant tremors, and lack complete volitional muscle control, this may place the shoulder at elevated risks of implant loosening and instability events.

In the present review, reoperations inclusive of revisions occurred at a pooled rate of 5.6%, with revision arthroplasty accounting for 99.3% of described reoperations (398 of 401). In studies with matched cohorts, PD demonstrated higher reoperation rates than their respective RSA control groups.^{2,4} Similarly, Burrus et al³ demonstrated an independent increase in revision rates after HA, aTSA, and RSA when compared with matched controls in a large national database investigation. In a review of their indications for revisions, they included traditionally common reasons for revision SA: instability, infection, periprosthetic fracture, and component loosening. As such, the observed increased risk of complications in patients with PD remains multifactorial and likely stems from the underlying manifestations of the disease, including the motor and nonmotor components. Interestingly, when reoperation was compared by implant type, RSA demonstrated a lower pooled rate of 1.9% than the 9.0% in aTSA and 7.1% in HA. This may suggest that RSA may be more accommodating of PD with respect to subsequent revision. However, this outcome may also be limited by the shorter follow-up of RSA studies because of the more recent introduction of the implant as compared to HA and aTSA.

Although this systematic review provides a broad overview of SA in the context of PD, it should be viewed within the context of certain limitations. The present investigation limited the search to articles with full text published in the English language, which may have resulted in exclusion of other relevant literature as well as potential selection bias. Subsequently, this study included many heterogenous retrospective studies spanning multiple decades with different numbers of patients, follow-up intervals, measured clinical outcomes, and varied implant use with unknown details on the surgical indications. In addition, most of the included patients

Table 3

Postoperative shoulder-related complications, reoperations, and revision rates per study.

Koch et al (1997)aTSA – 7 (43,8%) total: 3 (18.8%) sequic humeral component loosening 2 (12.5%) supturation 2 (12.5%) supturation 2 (12.5%) supturation 3 (5.1%) aspetic glenoid looseningaTSA – 3 (18.8%) revisions in total: 3 (18.1%) glenoid loosening 3 (5.1%) aspetic glenoid loosening 3 (5.1%) instability 2 (4.1%) asymptomatic glenoid loosening 3 (5.1%) instability 2 (4.1%) asymptomatic glenoid loosening 1 (2%) periprosthetic fracture 1 (3.3%) presistent pain 1 (3.3%) presistent pain 1 (3.3%) presistent pain 1 (3.3%) periprosthetic fracture 1 (3.3%) periprosthetic fracture 1 (3.3%) presistent pain 1 (3.3%) periprosthetic fracture 1 (3.2%) periprosthetic fracture 1 (3.2%) periprosthetic fractures 1 (3.6 (5.1%) infinited) 1 (4.2%) stotal: 2 (4.4%) stotal: 2 (4.4%) s
3 (18.83) aspric humeral component losening2 (12.5%) symptomatic subluxation2 (12.5%) subluxation1 (6.3%) glenoid losening2 (12.5%) aspric glenoid losening1 (6.3%) glenoid losening3 (5.1%) aspric glenoid losening3 (5.1%) aspric glenoid losening3 (5.1%) aspric found losening3 (5.1%) aspric glenoid losening3 (5.1%) aspric found losening3 (5.1%) aspric found losening3 (5.1%) aspric foundatic glenoid shifts1 (2%) perjorsthetic facture1 (2%) aspric humeral component losening1 (2%) perjorsthetic facture1 (2%) aspric humeral component losening1 (2%) perjorsthetic facture1 (2%) greater tuberosity nalunion1 (2%) greater tuberosity nalunion1 (14.3%) greater tuberosity nalunion1 (33.3%) revisions in total:1 (33.3%) persistent pain1 (33.3%) revisions in total:1 (33.3%) persistent pain1 (33.3%) revisions in total1 (33.3%) persistent pain1 (33.3%) revisions in total1 (33.3%) persistent pain1 (33.3%) revisions in total200 (r.4%) stiffness1 (3
2(12.5%) subbaction1 (6.3%) glenoid loosening $2(12.5%)$ sacptic glenoid looseningaTSA - 10 (20.4%) total:aTSA - 8 (16.3%) revisions in total: $3(6.1%)$ aspetic glenoid loosening3 (6.1%) aspetic glenoid loosening3 (6.1%) aspetic glenoid loosening $3(6.1%)$ aspetic is period loosening3 (6.1%) aspetic glenoid loosening3 (6.1%) aspetic humeral component loosening $1(2%)$ aspetic humeral component loosening1 (2%) aspetic humeral component loosening1 (2%) periprosthetic fracture $1(23)$ periprosthetic fractureHA - 4 (57.1%) total:HA - 0 (0%) revisions in total $3(42.9%)$ greater tuberosity malunion1 (33.3%) periprosthetic fracture1 (33.3%) periprosthetic fractureDunn et al (2011) ⁶ RSA - 3 (100%) total:RSA - 3 (100%) revisions in total: $(33.3%)$ periprosthetic fracture1 (33.3%) periprosthetic fracture1 (33.3%) periprosthetic fracture $1(33.3%)$ periprosthetic fracture1 (33.3%) periprosthetic fracture1 (33.2%) periprosthetic fracture1 (33.3%) periprosthetic fracture1 (33.2%) periprosthetic fracture1 (33.3%) periprosthetic
$ \begin{array}{c} 2 (12.5\%) a \operatorname{septic} glenoid loosening \\ 4 TSA - B (16.3\%) revisions in total: \\ 3 (6.1\%) aseptic glenoid loosening \\ 3 (6.1\%) aseptic numeral component loosening \\ 1 (2\%) aseptic humeral component loosening \\ 1 (2\%) aseptic humeral component loosening \\ 1 (2\%) aseptic humeral component loosening \\ 1 (2\%) greater tuberosity malunion \\ 1 (4.3\%) greater tuberosity malunion \\ 1 (3.3\%) periprosthetic fracture \\ 1 (3.3.3\%) instability \\ $
$ \begin{array}{llllllllllllllllllllllllllllllllllll$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
$ \begin{array}{c} 3 \ (6.18) \ (nrstability \\ 2 \ (4.18) \ asymptomatic glenois offsts \\ 1 \ (28) \ aseptic humeral component losening \\ 1 \ (28) \ aseptic humeral component losening \\ 1 \ (28) \ perjorosthetic fracture \\ 1 \ (33.38) \ perj$
$ \begin{array}{llllllllllllllllllllllllllllllllllll$
$ \begin{array}{llllllllllllllllllllllllllllllllllll$
$ \begin{array}{c} 1 (2%) \mbox{ periprosthetic fracture} \\ HA - 4 (57.1\%) total: HA - 0 (0\%) revisions in total \\ 3 (42.9%) \mbox{ greater tuberosity nalunion} \\ 1 (14.3%) \mbox{ greater tuberosity nonunion} \\ 1 (14.3%) \mbox{ greater tuberosity nonunion} \\ 1 (33.3%) \mbox{ periprosthetic fracture} \\ 1 (33.3%) \mbox{ periprosthetic fractures} \\ 6 (2.3%) \mbox{ periprosthetic fractures} \\ 1 (35.6%) \mbox{ periprosthetic fractures} \\ 1 (35.6%) \mbox{ periprosthetic fractures} \\ 6 (2.3%) \mbox{ periprosthetic fractures} \\ 1 (30.2%) \mbox{ periprosthetic fractures} \\ 1 (30.2%) periprosthetic fr$
Kryzac et al (2010)HA – 4 (57.1%) total:HA – 0 (0%) revisions in total 3 (42.9%) greater tuberosity malunion 1 (14.3%) greater tuberosity nonunionDunn et al (2011)RSA – 3 (100%) total:RSA – 3 (100%) revisions in total: 1 (33.3%) periprosthetic fracture1 (33.3%) periprosthetic fracture8 urrus et al (2015)HA – 704 (24.8%) total:HA – 158 (5.6%) revisions in total209 (7.4%) stiffness1 (32.2%) periprosthetic fractures6 (2.3%) infections35 (1.2%) aseptic component looseningHA – 158 (5.6%) revisions in total209 (7.4%) stiffness138 (5.6%) unlisted need for revision145 (5.1%) dislocations13 (32.2%) periprosthetic fractures66 (2.3%) infections13 (32.2%) periprosthetic fractures66 (2.3%) infections35 (1.2%) aseptic component loosening31 (3.2%) periprosthetic fractures66 (2.3%) infections31 (3.2%) periprosthetic fractures66 (2.3%) infections39 (5.2%) aseptic component looseningaTSA – 190 (5.6%) revisions in total237 (7.0%) stiffness39 (5.6%) aseptic component loosening34 (1.0%) peripro
$ \begin{array}{ll} 3(42.9\%) greater tuberosity malunion \\ 1(14.3\%) greater tuberosity nonunion \\ 1(33.3\%) perisions in total: \\ RSA - 3 (100\%) revisions in total: \\ 1(33.3\%) perisions the tal: \\ 1(33.3\%) instability \\ 1(33.3\%) instability \\ 1(33.3\%) instability \\ 1(33.3\%) perisions in total \\ 209 (7.4\%) stiffness \\ 209 (7.4\%) stiffness \\ 201 (2.4\%) total: \\ 203 (2.4\%) total: \\ 203 (2.4\%) stiffness \\ 201 (2.4\%) stiffness \\ 201 (2.4\%) total: \\ 203 (2.4\%) total: \\ 203 (2.4\%) stiffness \\ 201 (2.4\%) total: \\ 203 (2.4\%) stiffness \\ 201 (2.4\%) total: \\ 203 (2.4\%) stiffness \\ 201 (2.4\%) total: \\ 203 (2.4\%$
$\begin{array}{llllllllllllllllllllllllllllllllllll$
Dunn et al (2011)5RSA - 3 (100%) total:RSA - 3 (100%) revisions in total: 1 (33.3%) periprosthetic fracture1 (33.3%) instability1 (33.3%) periprosthetic fractureBurrus et al (2015)3HA - 704 (24.8%) total:HA - 158 (5.6%) revisions in total209 (7.4%) stiffness158 (5.6%) unlisted need for revisionHA - 158 (5.6%) revisions in total19 (3.2%) periprosthetic fractures66 (2.3%) infectionsHA - 158 (5.6%) revisions in total209 (7.4%) stiffness158 (5.6%) unlisted need for revisionHA - 158 (5.6%) revisions in total209 (7.4%) stiffness158 (5.6%) unlisted need for revisionHA - 158 (5.6%) revisions in total209 (7.4%) stiffness163.2%) periprosthetic fractures66 (2.3%) infections35 (1.2%) aseptic component loosening145 (5.1%) dislocationsHA - 158 (5.6%) revisions in total209 (7.4%) stiffness163.2%) periprosthetic fractures66 (2.3%) infections35 (1.2%) aseptic component loosening35 (1.2%) aseptic component loosening132.7 (7.0%) stiffness310 (5.6%) unlisted need for revision136 (4.0%) dislocations159 (5.6%) revisions in total237 (7.0%) stiffness190 (5.6%) unlisted need for revision136 (4.0%) dislocations39 (5.6%) aseptic component loosening39 (5.6%) aseptic component loosening132 (4.1%) revisions in total39 (5.6%) aseptic component loosening34 (1.0%) periprosthetic fracturesFSA - 33 (4.1%) revisions in total <t< td=""></t<>
$ \begin{array}{c} 1 (33.3\%) \ peristent pain \\ 1 (33.3\%) \ peristent pain \\ 1 (33.3\%) \ periprosthetic fracture \\ 1 (33.3\%) \ periprosthetic fractures \\ 1$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
$ \begin{array}{c} 1 (33.3\%) \text{ instability} & 1 (33.3\%) \text{ instability} \\ \text{HA} - 704 (24.8\%) \text{ total:} & \text{HA} - 158 (5.6\%) \text{ revisions in total} \\ 209 (7.4\%) \text{ stiffness} \\ 158 (5.6\%) \text{ unlisted need for revision} \\ 145 (5.1\%) \text{ dislocations} \\ 91 (3.2\%) \text{ periporshetic fractures} \\ 66 (2.3\%) \text{ infections} \\ 35 (1.2\%) \text{ aspectic component losening} \\ \text{HA} - 704 (24.8\%) \text{ total:} & \text{HA} - 158 (5.6\%) \text{ revisions in total} \\ 209 (7.4\%) \text{ stiffness} \\ 158 (5.6\%) \text{ unlisted need for revision} \\ 145 (5.1\%) \text{ dislocations} \\ 158 (5.6\%) \text{ unlisted need for revision} \\ 145 (5.1\%) \text{ dislocations} \\ 158 (5.6\%) \text{ unlisted need for revision} \\ 145 (5.1\%) \text{ dislocations} \\ 91 (3.2\%) \text{ periporshetic fractures} \\ 66 (2.3\%) \text{ infections} \\ 35 (1.2\%) \text{ appeting thetic fractures} \\ 66 (2.3\%) \text{ infections} \\ 35 (1.2\%) \text{ appeting thetic fractures} \\ 66 (2.3\%) \text{ infections} \\ 35 (1.2\%) \text{ appeting thetic fractures} \\ 66 (2.3\%) \text{ infections} \\ 35 (1.2\%) \text{ appeting thetic fractures} \\ 66 (2.3\%) \text{ infections} \\ 35 (1.2\%) \text{ appeting thetic fractures} \\ 66 (2.3\%) \text{ infections} \\ 35 (1.2\%) \text{ appeting thetic fractures} \\ 190 (5.6\%) \text{ unlisted need for revision} \\ 136 (4.0\%) \text{ dislocations} \\ 55 (1.6\%) \text{ infections} \\ 39 (5.6\%) \text{ appeting thetic fractures} \\ 39 (5.6\%) \text{ appeting thetic fractures} \\ 190 (5.6\%) \text{ unlisted need for revision} \\ 136 (4.0\%) \text{ dislocations} \\ 55 (1.6\%) \text{ infections} \\ 39 (5.6\%) \text{ appeting thetic fractures} \\ 30 (5.6\%) \text{ total:} \\ 30 $
Burrus et al (2015) ³ HA – 704 (24.8%) total: HA – 158 (5.6%) revisions in total 209 (7.4%) stiffness 158 (5.6%) unlisted need for revision 145 (5.1%) dislocations 91 (3.2%) periprosthetic fractures 66 (2.3%) infections 35 (1.2%) aseptic component loosening HA – 704 (24.8%) total: HA – 158 (5.6%) revisions in total 209 (7.4%) stiffness 158 (5.6%) unlisted need for revision 145 (5.1%) dislocations 91 (3.2%) periprosthetic fractures 66 (2.3%) infections 158 (5.6%) unlisted need for revision 145 (5.1%) dislocations 91 (3.2%) periprosthetic fractures 66 (2.3%) infections 35 (1.2%) aseptic component loosening aTSA – 691 (20.4%) total: aTSA – 190 (5.6%) revisions in total 237 (7.0%) stiffness 190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures 65 (1.6%) infections 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures 65 A = 33 (4.1%) revisions in total
209 (7.4%) stiffness 158 (5.6%) unlisted need for revision 145 (5.1%) dislocations 91 (3.2%) periprosthetic fractures 66 (2.3%) infections 35 (1.2%) aseptic component loosening HA - 704 (24.8%) total: HA - 158 (5.6%) revisions in total 209 (7.4%) stiffness 158 (5.6%) unlisted need for revision 145 (5.1%) dislocations 91 (3.2%) periprosthetic fractures 66 (2.3%) infections 35 (1.2%) aseptic component loosening aTSA - 691 (20.4%) total: aTSA - 190 (5.6%) revisions in total 237 (7.0%) stiffness 190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component loosening 41 (1.0%) periprosthetic fractures 63 (4.0%) dislocations 54 (1.0%) periprosthetic fractures 64 (1.0%) periprosthetic fractures 55 (1.6%) infections 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures 65 (1.2%) aseptic component loosening 34 (1.0%) periprosthetic fractures 55 (1.6%) infections 56 (1.5%) total: 57 (1.5%) total: 57 (1.6%) infections 59 (1.5%) total: 50 (1.5%) to
158 (5.6%) unlisted need for revision145 (5.1%) dislocations91 (3.2%) periprosthetic fractures66 (2.3%) infections35 (1.2%) aseptic component looseningHA - 704 (24.8%) total:HA - 158 (5.6%) revisions in total209 (7.4%) stiffness158 (5.6%) unlisted need for revision145 (5.1%) dislocations91 (3.2%) periprosthetic fractures66 (2.3%) infections35 (1.2%) aseptic component looseningaTSA - 691 (20.4%) total:aTSA - 691 (20.4%) total:aTSA - 190 (5.6%) revisions in total237 (7.0%) stiffness190 (5.6%) unlisted need for revision136 (4.0%) dislocations55 (1.6%) infections39 (5.6%) aseptic component loosening39 (5.6%) aseptic component loosening34 (1.0%) periprosthetic fracturesFSA = 175 (21 6%) total:FSA = 175 (21 6%) total:
145 (5.1%) dislocations91 (3.2%) periprosthetic fractures66 (2.3%) infections35 (1.2%) aseptic component loseningHA - 704 (24.8%) total:HA - 704 (24.8%) total:HA - 704 (24.8%) total:HA - 158 (5.6%) revisions in total209 (7.4%) stiffness158 (5.6%) unlisted need for revision145 (5.1%) dislocations91 (3.2%) periprosthetic fractures66 (2.3%) infections35 (1.2%) aseptic component loseningaTSA - 691 (20.4%) total:aTSA - 691 (20.4%) total:aTSA - 190 (5.6%) revisions in total237 (7.0%) stiffness190 (5.6%) unlisted need for revision136 (4.0%) dislocations55 (1.6%) infections39 (5.6%) aseptic component losening319 (5.6%) aseptic component losening319 (5.6%) aseptic component losening321 (1.0%) periprosthetic fractures33 (4.1%) periprosthetic fractures34 (1.0%) periprosthetic fracturesRSA = 175 (21.6%) total:RSA = 175 (21.6%) total:RSA = 175 (21.6%) total:
91 (3.2%) periprosthetic fractures 66 (2.3%) infections 35 (1.2%) aseptic component loosening HA $-$ 704 (24.8%) total: 209 (7.4%) stiffness 158 (5.6%) unlisted need for revision 145 (5.1%) dislocations 91 (3.2%) periprosthetic fractures 66 (2.3%) infections 35 (1.2%) aseptic component loosening aTSA $-$ 691 (20.4%) total: 237 (7.0%) stiffness 190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component loosening 313 (4.0%) dislocations 55 (1.6%) infections 324 (1.0%) periprosthetic fractures BSA $-$ 33 (4.1%) revisions in total
66 (2.3%) infections35 (1.2%) aseptic component looseningHA - 704 (24.8%) total:HA - 704 (24.8%) total:209 (7.4%) stiffness158 (5.6%) unlisted need for revision145 (5.1%) dislocations91 (3.2%) periprosthetic fractures66 (2.3%) infections35 (1.2%) aseptic component looseningaTSA - 691 (20.4%) total:aTSA - 691 (20.4%) total:aTSA - 190 (5.6%) revisions in total136 (4.0%) dislocations55 (1.6%) infections39 (5.6%) aseptic component loosening316 (4.0%) dislocations55 (1.6%) infections39 (5.6%) aseptic component loosening34 (1.0%) periprosthetic fractures65 (2.16%) infections39 (5.6%) aseptic component loosening34 (1.0%) periprosthetic fracturesRSA = 175 (21.6%) itetal:RSA = 175 (21.6%) itetal:
$\begin{array}{llllllllllllllllllllllllllllllllllll$
$\begin{array}{llllllllllllllllllllllllllllllllllll$
209 (7.4%) stiffness 158 (5.6%) unlisted need for revision 145 (5.1%) dislocations 91 (3.2%) periprosthetic fractures 66 (2.3%) infections 35 (1.2%) aseptic component loosening aTSA – 691 (20.4%) total: 237 (7.0%) stiffness 190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures BSA = 175 (21.6%) total: BSA = 33 (4.1%) revisions in total
158 (5.6%) unlisted need for revision 145 (5.1%) dislocations 91 (3.2%) periprosthetic fractures 66 (2.3%) infections 35 (1.2%) aseptic component losening aTSA - 691 (20.4%) total: 237 (7.0%) stiffness 190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component losening 34 (1.0%) periprosthetic fractures BSA - 170 (21.6%) revisions in total BSA - 33 (4.1%) revisions in total
145 (5.1%) dislocations91 (3.2%) periprosthetic fractures66 (2.3%) infections35 (1.2%) aseptic component loseningaTSA - 691 (20.4%) total:aTSA - 691 (20.4%) total:aTSA - 190 (5.6%) revisions in total237 (7.0%) stiffness190 (5.6%) unlisted need for revision136 (4.0%) dislocations55 (1.6%) infections39 (5.6%) aseptic component losening34 (1.0%) periprosthetic fracturesRSA - 175 (21.6%) total:RSA - 190 (5.6%) revisions in total
91 (3.2%) periprosthetic fractures 66 (2.3%) infections 35 (1.2%) aseptic component losening aTSA - 691 (20.4%) total: 237 (7.0%) stiffness 190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component losening 34 (1.0%) periprosthetic fractures RSA - 130 (4.1%) revisions in total
66 (2.3%) infections35 (1.2%) aseptic component loseningaTSA - 691 (20.4%) total:aTSA - 691 (20.4%) total:aTSA - 190 (5.6%) revisions in total237 (7.0%) stiffness190 (5.6%) unlisted need for revision136 (4.0%) dislocations55 (1.6%) infections39 (5.6%) aseptic component losening34 (1.0%) periprosthetic fracturesRSA - 170 (21.6%) total:RSA - 33 (4.1%) revisions in total
35 (1.2%) aseptic component loosening aTSA - 691 (20.4%) total: 237 (7.0%) stiffness 190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures BSA - 175 (21.6%) total: BSA - 33 (4.1%) revisions in total
aTSA - 691 (20.4%) total: 237 (7.0%) stiffness 190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures BSA - 175 (21.6%) total: BSA - 33 (4.1%) revisions in total
237 (7.0%) stiffness 190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures RSA = 175 (21.6%) total: RSA = 33 (4.1%) revisions in total
190 (5.6%) unlisted need for revision 136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures RSA = 175 (21.6%) total: RSA = 33 (4.1%) revisions in total
136 (4.0%) dislocations 55 (1.6%) infections 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures RSA = 175 (21.6%) total: RSA = 33 (4.1%) revisions in total
55 (1.6%) infections 39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures RSA = 175 (21.6%) total: RSA = 33 (4.1%) revisions in total
39 (5.6%) aseptic component loosening 34 (1.0%) periprosthetic fractures RSA = 175 (21.6%) total: RSA = 33 (4.1%) revisions in total
34 (1.0%) periprosthetic fractures RSA – 175 (21.6%) total: RSA – 33 (4.1%) revisions in total
RSA = 175 (21.6%) total $RSA = 33$ (4.1%) revisions in total
59 (7.3%) stiffness
45 (5.6%) dislocations
33 (4.1%) unlisted need for revision
27 (3.3%) infections
11 (1.4%) periprosthetic fractures
Cusick et al $(2017)^4$ RSA – 4 (40%) total: RSA – 1 (10%) revision in total:
2 (20%) postoperative acromial fractures 1 (10%) case of recurrent instability
1 (10%) glenoid baseplate component failure
1 (10%) instability
Borbas et al (2021) ² RSA – 10 (58.8%) total: RSA – 5 (29.4%) reoperations in total:
3 (17.6%) postoperative scapular spine fracture 2 (11.8%) ORIF of scapular spine
2 (11.8%) periprosthetic humeral fracture 1 (5.9%) arthroscopic acromioplasty of scapular spine fracture
2 (11.8%) aseptic glenoid loosening 2 (11.8%) revisions in total
1 (5.9%) instability 1 (5.9%) periprosthetic humeral fracture
1 (5.9%) infection 1 (5.9%) acromial fracture
1 (5.9%) postoperative acromial fracture

aTSA, anatomic total shoulder arthroplasty; HA, hemiarthroplasty; RSA, reverse shoulder arthroplasty; ORIF, open reduction internal fixation.

were acquired from the study by Burrus et al,³ which heavily influences the current analysis, especially the rates of complications and revision surgery. Therefore, it was difficult to consistently pool all variables to generate a complete meta-analysis. As such, the present investigation performed a qualitative systematic review with quantitative calculations whenever feasible.

Conclusion

The results of the present systematic review demonstrate that SA in patients with PD likely results in consistent pain relief. However, inferior improvements in clinical outcomes may be expected, likely due to the neurodegenerative manifestations of this disorder. An elevated rate of complications was observed in the literature with a pooled rate of 22.5%. However, revisions were much lower with a 5.6% pooled rate. RSA may be the most accommodating implant type to PD, with a lower rate of revisions.

Disclaimers:

Funding: No funding was disclosed by the authors. Conflicts of interest: The authors, their immediate families, and any research foundation with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.

E.M. Marigi, H. Shah, J.W. Sperling Jr. et al.

Table 4

Pooled shoulder-related complications categorized by implant type.

Complications	HA(n=2840)		aTSA (n = 3455)		RSA (n = 839)		All SA (n =	= 7134)
	No.	%	No.	%	No.	%	No.	%
Stiffness	209	7.4	237	6.9	59	7.0	505	7.1
Unlisted need for revision	159	5.6	190	5.5	33	3.9	381	5.3
Instability	145	5.1	141	4.1	48	5.7	334	4.7
Infections	66	2.3	55	1.6	28	3.3	149	2.1
Periprosthetic fracture	91	3.2	35	1.0	14	1.7	140	2.0
Aseptic component loosening	35	1.2	39	1.1	0	0.0	74	1.0
Aseptic glenoid loosening	0	0.0	7	0.2	3	0.4	10	0.1
Acromial/scapular spine fractures	0	0.0	0	0.0	6	0.7	6	0.1
Aseptic humeral component loosening	0	0.0	4	0.1	0	0.0	4	0.1
Greater tuberosity malunion	3	0.1	0	0.0	0	0.0	3	0.0
Greater tuberosity nonunion	1	0.0	0	0.0	0	0.0	1	0.0
Total	709	25.0	708	20.5	191	22.8	1607	22.5

HA, hemiarthroplasty; aTSA, anatomic total shoulder arthroplasty; RSA, reverse shoulder arthroplasty; SA, shoulder arthroplasty.

All values are reported as the number and percentage except when noted.

Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jseint.2021.11.004.

References

- 1. Aita JF. Why patients with Parkinson's disease fall. JAMA 1982;247:515-6.
- Borbas P, Kriechling P, Fehler S, Bouaicha S, Wieser K. The influence of Parkinson's disease on outcome and complication rate of reverse total shoulder arthroplasty: a matched group Analysis. Orthopedics 2021;44:86-91. https:// doi.org/10.3928/01477447-20210217-02.
- Burrus MT, Werner BC, Cancienne JM, Gwathmey FW, Brockmeier SF. Shoulder arthroplasty in patients with Parkinson's disease is associated with increased complications. J Shoulder Elbow Surg 2015;24:1881-7. https://doi.org/10.1016/ j.jse.2015.05.048.
- Cusick MC, Otto RJ, Clark RE, Frankle MA. Outcome of reverse shoulder arthroplasty for patients with Parkinson's disease: a matched cohort study. Orthopedics 2017;40:e675-80. https://doi.org/10.3928/01477447-20170 509-03.
- Dunn J, Byrne AN, Higgins LD. Reverse total shoulder arthroplasty in patients with Parkinson disease: a case series and review of the literature. Am J Orthop (Belle Mead NI) 2011;40:625-9.
- Kim YE, Jeon BS. Musculoskeletal problems in Parkinson's disease. J Neural Transm (Vienna) 2013;120:537-42. https://doi.org/10.1007/s00702-012-0960-2.
- Koch LD, Cofield RH, Ahlskog JE. Total shoulder arthroplasty in patients with Parkinson's disease. J Shoulder Elbow Surg 1997;6:24-8.

- Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord 2013;28:311-8. https://doi.org/10.1002/mds.25292.
- Kryzak TJ, Sperling JW, Schleck CD, Cofield RH. Total shoulder arthroplasty in patients with Parkinson's disease. J Shoulder Elbow Surg 2009;18:96-9. https:// doi.org/10.1016/j.jse.2008.07.010.
- Kryzak TJ, Sperling JW, Schleck CD, Cofield RH. Hemiarthroplasty for proximal humerus fractures in patients with Parkinson's disease. Clin Orthop Relat Res 2010;468:1817-21. https://doi.org/10.1007/s11999-010-1353-1.
- Leibson CL, Maraganore DM, Bower JH, Ransom JE, O'Brien PC, Rocca WA. Comorbid conditions associated with Parkinson's disease: a population-based study. Mov Disord 2006;21:446-55. https://doi.org/10.1002/mds.20685.
- Macaulay W, Geller JA, Brown AR, Cote LJ, Kiernan HA. Total knee arthroplasty and Parkinson disease: enhancing outcomes and avoiding complications. J Am Acad Orthop Surg 2010;18:687-94. https://doi.org/10.5435/00124635-201011000-00006.
- Poewe W. The natural history of Parkinson's disease. J Neurol 2006;253:Vii2-6. https://doi.org/10.1007/s00415-006-7002-7.
- Queally JM, Abdulkarim A, Mulhall KJ. Total hip replacement in patients with neurological conditions. J Bone Joint Surg Br 2009;91:1267-73. https://doi.org/ 10.1302/0301-620x.91b10.22934.
- Simovitch R, Flurin PH, Wright T, Zuckerman JD, Roche CP. Quantifying success after total shoulder arthroplasty: the minimal clinically important difference. J Shoulder Elbow Surg 2018;27:298-305. https://doi.org/10.1016/ j.jse.2017.09.013.
- Tolosa E, Compta Y. Dystonia in Parkinson's disease. J Neurol 2006;253:Vii7-13. https://doi.org/10.1007/s00415-006-7003-6.
- Weber M, Cabanela ME, Sim FH, Frassica FJ, Harmsen WS. Total hip replacement in patients with Parkinson's disease. Int Orthop 2002;26:66-8. https:// doi.org/10.1007/s00264-001-0308-2.